Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124256670> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2124256670 endingPage "2476" @default.
- W2124256670 startingPage "2465" @default.
- W2124256670 abstract "In the last two decades, knowledge of the neurobiology of prion diseases or transmissible spongiform encephalopathies (TSE) has significantly advanced, but a successful therapy to stop or delay the progression of these disorders remains one of the most challenging goals of biomedical research. Several obstacles to this achievement are in common with other neurodegenerative disorders: difficulties to move from experimental level to clinical stage; appropriate timing of intervention; correct set up of clinical trial. Also in terms of molecular bases of disease, TSE and the other neurodegenerative disorders associated with protein misfolding such as Alzheimer, Parkinson and Huntington diseases, share a central pathogenic role of soluble small aggregates, named oligomers, considered the culprit of neuronal dysfunction: accordingly, these disorders could by termed oligomeropathies. However, the rapid progression of TSE, together with their clinical and molecular heterogeneity, make the therapeutic approach particularly problematic. The main target of the antiprion strategy has been the pathological form of the cellular prion protein (PrPC) termed PrPSc, invariably associated with the diseases. Several compounds have been found to affect PrPSc formation or enhance its clearance in in vitro models, and prolong survival in experimental animals. However, few of them such as quinacrine and pentosan polysulfate have reached the clinical evaluation; more recently, we have conducted a clinical trial with doxycycline in patients with Creutzfeldt-Jakob disease without satisfactory results. In experimental conditions, active and passive immunization with antibodies against PrP and mucosal vaccination have shown to protect from peripheral infection. Other studies have proposed new potentially effective molecules targeting PrP oligomers. Furthermore, the possibility to interfere with PrPC to PrPSc conversion by an active control of PrPC is another interesting approach emerging from experimental studies. However, in common with the other oligomeropathies, early diagnosis allowing to treat at risk population in a preclinical stage represent the more realistic perspective for efficient TSE therapy. Keywords: Clinical trials, immunotherapy, presymtomatic treatment, prion diseases, prion protein, oligomers, therapeutic targets." @default.
- W2124256670 created "2016-06-24" @default.
- W2124256670 creator A5004166000 @default.
- W2124256670 creator A5012971731 @default.
- W2124256670 creator A5013765311 @default.
- W2124256670 creator A5072555597 @default.
- W2124256670 creator A5074273853 @default.
- W2124256670 date "2013-10-01" @default.
- W2124256670 modified "2023-09-26" @default.
- W2124256670 title "Therapy in Prion Diseases" @default.
- W2124256670 doi "https://doi.org/10.2174/15680266113136660173" @default.
- W2124256670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24059336" @default.
- W2124256670 hasPublicationYear "2013" @default.
- W2124256670 type Work @default.
- W2124256670 sameAs 2124256670 @default.
- W2124256670 citedByCount "39" @default.
- W2124256670 countsByYear W21242566702014 @default.
- W2124256670 countsByYear W21242566702015 @default.
- W2124256670 countsByYear W21242566702016 @default.
- W2124256670 countsByYear W21242566702017 @default.
- W2124256670 countsByYear W21242566702018 @default.
- W2124256670 countsByYear W21242566702019 @default.
- W2124256670 countsByYear W21242566702020 @default.
- W2124256670 countsByYear W21242566702021 @default.
- W2124256670 countsByYear W21242566702022 @default.
- W2124256670 countsByYear W21242566702023 @default.
- W2124256670 crossrefType "journal-article" @default.
- W2124256670 hasAuthorship W2124256670A5004166000 @default.
- W2124256670 hasAuthorship W2124256670A5012971731 @default.
- W2124256670 hasAuthorship W2124256670A5013765311 @default.
- W2124256670 hasAuthorship W2124256670A5072555597 @default.
- W2124256670 hasAuthorship W2124256670A5074273853 @default.
- W2124256670 hasConcept C142724271 @default.
- W2124256670 hasConcept C169760540 @default.
- W2124256670 hasConcept C2777179404 @default.
- W2124256670 hasConcept C2779134260 @default.
- W2124256670 hasConcept C2780035454 @default.
- W2124256670 hasConcept C2994543053 @default.
- W2124256670 hasConcept C501593827 @default.
- W2124256670 hasConcept C535046627 @default.
- W2124256670 hasConcept C60644358 @default.
- W2124256670 hasConcept C71924100 @default.
- W2124256670 hasConcept C86803240 @default.
- W2124256670 hasConcept C89423630 @default.
- W2124256670 hasConcept C98274493 @default.
- W2124256670 hasConceptScore W2124256670C142724271 @default.
- W2124256670 hasConceptScore W2124256670C169760540 @default.
- W2124256670 hasConceptScore W2124256670C2777179404 @default.
- W2124256670 hasConceptScore W2124256670C2779134260 @default.
- W2124256670 hasConceptScore W2124256670C2780035454 @default.
- W2124256670 hasConceptScore W2124256670C2994543053 @default.
- W2124256670 hasConceptScore W2124256670C501593827 @default.
- W2124256670 hasConceptScore W2124256670C535046627 @default.
- W2124256670 hasConceptScore W2124256670C60644358 @default.
- W2124256670 hasConceptScore W2124256670C71924100 @default.
- W2124256670 hasConceptScore W2124256670C86803240 @default.
- W2124256670 hasConceptScore W2124256670C89423630 @default.
- W2124256670 hasConceptScore W2124256670C98274493 @default.
- W2124256670 hasIssue "19" @default.
- W2124256670 hasLocation W21242566701 @default.
- W2124256670 hasLocation W21242566702 @default.
- W2124256670 hasOpenAccess W2124256670 @default.
- W2124256670 hasPrimaryLocation W21242566701 @default.
- W2124256670 hasRelatedWork W1501007924 @default.
- W2124256670 hasRelatedWork W2089509941 @default.
- W2124256670 hasRelatedWork W2091749935 @default.
- W2124256670 hasRelatedWork W2372770165 @default.
- W2124256670 hasRelatedWork W2377626647 @default.
- W2124256670 hasRelatedWork W2406498910 @default.
- W2124256670 hasRelatedWork W2488561559 @default.
- W2124256670 hasRelatedWork W2617104414 @default.
- W2124256670 hasRelatedWork W2903012975 @default.
- W2124256670 hasRelatedWork W4236742180 @default.
- W2124256670 hasVolume "13" @default.
- W2124256670 isParatext "false" @default.
- W2124256670 isRetracted "false" @default.
- W2124256670 magId "2124256670" @default.
- W2124256670 workType "article" @default.